Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia

J Clin Psychiatry. 2004;65 Suppl 7:4-18; quiz 19-20.
No abstract available

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Adult
  • Antipsychotic Agents / adverse effects*
  • Antipsychotic Agents / therapeutic use
  • Cardiovascular Diseases / chemically induced
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / mortality
  • Cause of Death
  • Diabetic Ketoacidosis / chemically induced
  • Diabetic Ketoacidosis / epidemiology
  • Diabetic Ketoacidosis / mortality
  • Drug Monitoring
  • Female
  • Humans
  • Hyperlipidemias / chemically induced
  • Hyperlipidemias / epidemiology
  • Hyperlipidemias / mortality
  • Insulin Resistance
  • Male
  • Metabolic Syndrome / chemically induced*
  • Metabolic Syndrome / epidemiology
  • Metabolic Syndrome / mortality
  • Myocardial Infarction / chemically induced
  • Myocardial Infarction / epidemiology
  • Myocardial Infarction / mortality
  • Obesity / chemically induced*
  • Obesity / epidemiology
  • Obesity / mortality
  • Prevalence
  • Risk Factors
  • Schizophrenia / drug therapy*
  • Schizophrenia / mortality*
  • Weight Gain / drug effects*

Substances

  • Antipsychotic Agents